On Monday, April 18, 2022, the U.S. Food and Drug Administration (FDA) approved Alymsys® (bevacizumab-maly), a biosimilar to Avastin® (bevacizumab). Alymsys' approved indications include:
Read Brand Institute's announcement for more information.
Posted 4/18/2022
In recognition of Leukemia and Lymphoma Awareness Month, ACCC compiled a group of resources to help care teams navigate two of the most commonly diagnosed adult leukemias: acute myeloid leukemia and chronic lymphocytic leukemia.
